BioSpace News Archive

Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders

As part of Operation Warp Speed, the U.S. government’s public-private partnership to deliver COVID-19 vaccines to Americans, and under the direction of the Centers for Disease Control and Prevention, McKesson began distributing Moderna’s COVID-19 vaccines and the ancillary supply kits needed to administer them.

Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology

Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population

Followed by Russia, Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020.

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced positive efficacy and safety results from a Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer.